2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow T2D: new trials by email Literature Review of T2D trials Research Report on T2D
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) Insulin Efsitora Alfa, Insulin Glargine - Type 2 Diabetes, T2D | Phase 3 | Completed | Eli Lilly and Company | 795 | 2023-01-14 | 2025-08-06 |
| A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo - Type2 Diabetes, Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 99 | 2022-04-13 | 2025-09-26 |
Diabetes Mellitus, Type 2 (2) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1)
Nutritional and Metabolic Diseases (2) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1)
Insulin Glargine (1)
Mexico (2) · United States (2) · Argentina (1) · Australia (1) · Brazil (1) · France (1) · India (1) · Israel (1) · Italy (1) · Puerto Rico (1) · United Kingdom (1)